LOGIN  |  REGISTER
Cue Biopharma
Recursion

Vor to Participate in Piper Sandler 33rd Virtual Annual Healthcare Conference

November 19, 2021 | Last Trade: US$1.60 0.14 -8.05

Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Dr. Robert Ang, Vor’s President and Chief Executive Officer, will be participating at the Piper Sandler 33rd Virtual Annual Healthcare Conference.

Piper Sandler 33rd Virtual Annual Healthcare Conference

Date: Tuesday, November 30 through Thursday, December 2, 2021

Vor’s pre-recorded presentation will be available on-demand from Piper Sandler beginning on Monday, November 22nd at 10:00 am ET and can also be accessed via the Investors section of the Company's website at www.vorbio.com

About Vor Biopharma

Vor Biopharma is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.

Contacts:

Investors:
Chris Brinzey
ICR Westwicke
+1 339-970-2843
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Media:
Vice President, Corporate Communications, Vor
Sarah Spencer
+1 857-242-6076
This email address is being protected from spambots. You need JavaScript enabled to view it. 


Viking Therapeutics

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page